REVB

Revelation Biosciences, Inc. NASDAQ Listed Nov 17, 2020

Healthcare ·Biotechnology ·US · revbiosciences.com

$1.02

After hrs $0.95 -1.04%

Mkt Cap $3.8M

52w Low $0.99 0.1% of range 52w High $40.08

50d MA $1.20 200d MA $4.48

P/E (TTM) -0.1x

EV/EBITDA 0.9x

P/B 0.1x

Debt/Equity 0.1x

ROE -100.6%

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta -0.17

50d MA $1.20

200d MA $4.48

Avg Volume 140.7K

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

SIC Code

2834

CIK (SEC)

1810560

Phone

650 800 3717

4660 La Jolla Village Drive · San Diego, CA 92122 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 7, 2026	AMC	-1.15	-2.71	-135.7%	—	—	—	—	—	—	—	—
Feb 26, 2026	AMC	-3.66	-1.65	+54.9%	1.33	+0.8%	-0.8%	-3.0%	-7.5%	-6.0%	-6.8%	—
Nov 6, 2025	AMC	-5.36	-7.08	-32.1%	4.04	-2.0%	-3.0%	+3.0%	-1.0%	-2.7%	-9.7%	—
Aug 7, 2025	AMC	-4.46	-7.01	-57.2%	10.20	-2.7%	-6.7%	-6.7%	-5.1%	-1.2%	+1.2%	—
May 8, 2025	AMC	-20.64	-6.33	+69.3%	37.16	-1.8%	+2.6%	+5.3%	+2.7%	+1.1%	-2.2%	—
Mar 6, 2025	AMC	-9.60	-14.94	-55.6%	41.52	-1.7%	+0.9%	-2.9%	-3.5%	-1.7%	-5.5%	—
Nov 8, 2024	AMC	-136.33	-40.32	+70.4%	157.44	+23.2%	+26.8%	+18.6%	+11.0%	+2.0%	-2.1%	—
Aug 9, 2024	AMC	-86.89	-73.93	+14.9%	192.00	+0.0%	-7.7%	-10.0%	-9.7%	-10.5%	-13.9%	—
May 10, 2024	AMC	-258.75	-118.09	+54.4%	395.52	-1.0%	-10.7%	-10.4%	-5.3%	-9.7%	-1.9%	—
Mar 22, 2024	AMC	-525.17	-399.88	+23.9%	455.04	+0.8%	+0.8%	+9.7%	+2.5%	+15.6%	+12.2%	—
Nov 9, 2023	AMC	-432.48	-591.05	-36.7%	3356.92	-3.0%	-3.9%	-2.2%	+5.5%	+8.2%	+16.0%	—
Aug 11, 2023	AMC	-475.72	-360.40	+24.2%	4320.00	-1.3%	-2.5%	-4.5%	-4.6%	-7.7%	-5.4%	—
May 22, 2023	AMC	-937.03	-735.21	+21.5%	6854.40	-0.8%	-4.2%	-7.6%	-5.9%	-7.6%	-12.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 13	Roth MKM	Maintains	Buy → Buy	—	$16416.00	$16704.00	+1.8%	+0.4%	-5.3%	-4.2%	-7.4%	-13.0%
Feb 17	Roth Capital	Maintains	Buy → Buy	—	$449567.32	$463679.28	+3.1%	-27.4%	-34.1%	-30.9%	-6.7%	-22.4%

Data updated apr 26, 2026 10:31pm · Source: massive.com